Exclusive Manufacturer Sanofi has told GPs that it is reducing their orders of the QIVe flu vaccine for the 2021/22 season by 30% due to an ‘increase in global demand’, Pulse has learned.
An email sent out this morning to affected customers including GP practices suggests they should considering another supplier, or contact Sanofi to source an alternative flu vaccine.
Pulse last month reported that GPs were concerned around shortages of flu vaccines after the Government announced that it will not be holding a central stock as it did last year, despite continuing the expanded cohorts from the 2020/21 season.
The email from Sanofi said: ‘We are sorry to inform you that, due to an increase in global demand, we unfortunately need to reduce your order from Sanofi Pasteur for QIVe.
‘As a result, we are unable to fulfil 30% of your order of QIVe for the 2021/22 season. These doses will be automatically reduced from your order.’
A spokesperson for the company told Pulse: ‘We have informed customers in the UK that due to global demand, we would be unable to fulfil 30% of QIVe orders for the upcoming 2021 season.
‘Affected customers have been contacted and have been provided options to secure additional vaccine doses. We are working to support customers affected during these unprecedented times.’
They added that the company manufactures ‘the maximum number of flu vaccines that our global capacity allows’ and is ‘continuously’ working to increase capacity ‘with significant industrial investments’.
‘Last season, we distributed more influenza vaccine doses than we ever have before – and have further improved on that increase again this year,’ the spokesperson said.